MCID: CNN004
MIFTS: 45

Connective Tissue Cancer

Categories: Cancer diseases

Aliases & Classifications for Connective Tissue Cancer

MalaCards integrated aliases for Connective Tissue Cancer:

Name: Connective Tissue Cancer 12 15
Neoplasms, Connective Tissue 44 73
Neoplasm of Connective Tissues 12
Tumour of Connective Tissue 12
Connective Tissue Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:201
MeSH 44 D009372
SNOMED-CT 68 126598008 254821003
UMLS 73 C0027656

Summaries for Connective Tissue Cancer

Disease Ontology : 12 A musculoskeletal system cancer that is located in connective tissue.

MalaCards based summary : Connective Tissue Cancer, also known as neoplasms, connective tissue, is related to bone cancer and sarcoma. An important gene associated with Connective Tissue Cancer is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Dienogest and Nandrolone decanoate have been mentioned in the context of this disorder. Affiliated tissues include connective tissue, bone and t cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Connective Tissue Cancer

Diseases in the Connective Tissue Cancer family:

Connective Tissue Benign Neoplasm

Diseases related to Connective Tissue Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 98)
# Related Disease Score Top Affiliating Genes
1 bone cancer 32.4 CD99 COL1A1 EWSR1 TRPV1
2 sarcoma 29.6 CREB3L2 EWSR1 FUS PDGFB SS18 SSX1
3 connective tissue benign neoplasm 11.2
4 epithelioid cell synovial sarcoma 11.1 SSX1 SSX2B
5 zika virus infection 11.1 MDM2 TP53
6 ring chromosome 4 11.1 COL1A1 PDGFB
7 bladder sarcoma 11.1 CD99 EWSR1
8 tibial adamantinoma 11.1 CD34 SSX1
9 extraskeletal mesenchymal chondrosarcoma 11.1 SSX1 SSX2B
10 cellular neurofibroma 11.1 CD34 TP53
11 actinic cheilitis 11.1 MDM2 TP53
12 testicular fibroma 11.0 CD34 CD99
13 conventional central osteosarcoma 11.0 EWSR1 MDM2
14 undifferentiated embryonal sarcoma of the liver 11.0 CDK4 MDM2
15 bone epithelioid hemangioma 11.0 CD34 EWSR1
16 soft tissue sarcoma 11.0 EWSR1 MDM2 TP53
17 bone osteosarcoma 11.0 CDK4 EWSR1 MDM2
18 bednar tumor 11.0 COL1A1 PDGFB
19 infiltrating angiolipoma 11.0 CDK4 MDM2
20 ring chromosome 7 11.0 CDK4 MDM2 TP53
21 retina lymphoma 11.0 CD34 CD68
22 spindle cell lipoma 11.0 CDK4 MDM2
23 dedifferentiated liposarcoma 11.0 CDK4 MDM2 TP53
24 small cell sarcoma 11.0 CDK4 MDM2 TP53
25 embryonal sarcoma 11.0 CDK4 MDM2 TP53
26 lipomatosis, multiple 11.0 CDK4 FUS MDM2
27 extraosseous osteosarcoma 11.0 CD34 CDK4 MDM2
28 extracutaneous mastocytoma 11.0 CD34 CD68
29 sternum cancer 11.0 CD34 CD68
30 retinal cancer 11.0 CDK4 MDM2 TP53
31 rhabdomyosarcoma 2 11.0 CDK4 EWSR1 MDM2
32 extraskeletal ewing sarcoma 11.0 CD99 EWSR1 FUS
33 sensory system cancer 11.0 CDK4 MDM2 TP53
34 ocular cancer 10.9 CDK4 MDM2 TP53
35 inflammatory mfh 10.9 CD68 CDK4 MDM2
36 cellular schwannoma 10.9 CD34 MDM2 TP53
37 grade iii astrocytoma 10.9 CDK4 MDM2 TP53
38 lip cancer 10.9 MDM2 TP53
39 myxosarcoma 10.9 CD68 MDM2 TP53
40 bone ewing's sarcoma 10.9 CD99 EWSR1 PDGFB
41 liver angiosarcoma 10.9 CD34 CDK4 TP53
42 melanotic neurilemmoma 10.9 CD34 CD68
43 fibrosarcoma of bone 10.9 CDK4 CREB3L2 MDM2
44 meninges sarcoma 10.9 CD34 CREB3L2 TP53
45 leiomyosarcoma 10.9 CDK4 MDM2 TP53
46 adult xanthogranuloma 10.9 CD34 CD68
47 sarcomatoid squamous cell skin carcinoma 10.9 CD34 CD68 TP53
48 kidney hemangiopericytoma 10.9 CD34 SS18 SSX2B
49 biphasic synovial sarcoma 10.9 EWSR1 SSX1
50 malignant peripheral nerve sheath tumor 10.9 CDK4 MDM2 TP53

Graphical network of the top 20 diseases related to Connective Tissue Cancer:



Diseases related to Connective Tissue Cancer

Symptoms & Phenotypes for Connective Tissue Cancer

GenomeRNAi Phenotypes related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.62 TLE1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.62 FUS
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.62 SSX2B
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.62 SSX2B
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.62 EWSR1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.62 SSX1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.62 EWSR1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.62 FUS
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.62 CDK4 EWSR1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.62 FUS TLE1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.62 CDK4 EWSR1 FUS SSX1 SSX2B TLE1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.62 EWSR1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.62 EWSR1

MGI Mouse Phenotypes related to Connective Tissue Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.63 CD34 CDK4 COL1A1 MDM2 TP53 TRPV1
2 pigmentation MP:0001186 9.35 CDK4 COL1A1 MDM2 PDGFB TP53
3 renal/urinary system MP:0005367 9.17 CAMKMT CDK4 COL1A1 MDM2 PDGFB TP53

Drugs & Therapeutics for Connective Tissue Cancer

Drugs for Connective Tissue Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 556)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dienogest Approved Phase 4 65928-58-7
2
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
3
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
4
Desogestrel Approved Phase 4 54024-22-5 40973
5
Goserelin Approved Phase 4,Phase 3 65807-02-5 47725 5311128
6
Calcium Carbonate Approved, Investigational Phase 4,Phase 3 471-34-1
7
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
8
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
9
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
10
Tamoxifen Approved Phase 4,Phase 2,Phase 1 10540-29-1 2733526
11
Anastrozole Approved, Investigational Phase 4,Phase 3 120511-73-1 2187
12
Menthol Approved Phase 4,Phase 3,Early Phase 1 2216-51-5 16666
13
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
14
Zinc Approved, Investigational Phase 4 7440-66-6 23994
15
Zinc oxide Approved Phase 4 1314-13-2
16
Letrozole Approved, Investigational Phase 4,Phase 1 112809-51-5 3902
17
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
18
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
19
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
20
Ibuprofen Approved Phase 4,Phase 2,Not Applicable 15687-27-1 3672
21
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
22
Morphine Approved, Investigational Phase 4,Phase 1,Phase 2 57-27-2 5288826
23
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
24
Ethanol Approved Phase 4,Phase 3 64-17-5 702
25
Mifepristone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 84371-65-3 55245
26
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53714-56-0 3911 657181
27
Denosumab Approved Phase 4,Phase 3,Phase 2 615258-40-7
28
Levonorgestrel Approved, Investigational Phase 4,Phase 1 797-63-7, 17489-40-6 13109
29
Misoprostol Approved Phase 4,Phase 2 59122-46-2 5282381
30
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 57-83-0 5994
31
Dalteparin Approved Phase 4,Phase 1,Not Applicable 9005-49-6
32
Heparin Approved, Investigational Phase 4,Phase 1,Not Applicable 9005-49-6 772 46507594
33
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 1 169590-42-5 2662
34
Tranexamic Acid Approved Phase 4,Early Phase 1 1197-18-8 5526
35
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
36
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
37
Enoxaparin Approved Phase 4 9005-49-6 772
38
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
39
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
41
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
42
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
43
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
44
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4 13422-55-4
45
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 59-67-6 938
46
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 98-92-0 936
47
Pyridoxal Approved, Nutraceutical Phase 4 66-72-8 1050
48
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
49
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
50
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130

Interventional clinical trials:

(show top 50) (show all 1174)
# Name Status NCT ID Phase Drugs
1 IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure Unknown status NCT02601196 Phase 4 Ulipristal acetate
2 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
3 Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
4 High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids Unknown status NCT01239641 Phase 4
5 Stereotactic Body Radiotherapy for Head and Neck Tumors Unknown status NCT01344356 Phase 4
6 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
7 Imatinib in KIT-negative Systemic Mastocytosis Completed NCT01297777 Phase 4 Imatinib Mesylate
8 Fibroids in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
9 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
10 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
11 The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids. Completed NCT00995878 Phase 4
12 Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
13 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
14 Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future Completed NCT00180739 Phase 4
15 Efficacy Study of Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Large Fibroids Completed NCT00159328 Phase 4
16 Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor Completed NCT00793871 Phase 4 Sunitinib Malate (SU011248)
17 Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate Completed NCT00510354 Phase 4 Imatinib mesylate
18 Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) Completed NCT00171977 Phase 4 Imatinib Mesylate
19 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
20 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer Completed NCT00999921 Phase 4 Tamoxifen;Evening Primrose Oil
21 Retreatment of Recurrent Dupuytren's Contractures Completed NCT01498640 Phase 4
22 MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex Completed NCT01450397 Phase 4
23 Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
24 Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb Completed NCT01265420 Phase 4
25 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
26 Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery Completed NCT01388907 Phase 4
27 A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
28 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
29 Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis Recruiting NCT03500367 Phase 4 rapamycin
30 A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy Recruiting NCT03210324 Phase 4 Mifepristone tablets
31 Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas Recruiting NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
32 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Recruiting NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
33 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Recruiting NCT03301857 Phase 4 Cohort A Denosumab
34 Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction Recruiting NCT02228889 Phase 4
35 Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids Recruiting NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
36 Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Recruiting NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
37 Trial Comparing Treatment Strategies in Dupuytren's Contracture Recruiting NCT03192020 Phase 4 Collagenase Clostridium Histolyticum 2.9 MG/ML [Xiaflex]
38 Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren's Disease Recruiting NCT03000114 Phase 4 XIAFLEX
39 The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib Recruiting NCT02800330 Phase 4 Esomeprazole 40mg concomitantly;Esomeprazole 40mg before;Regorafenib 160mg or 120mg
40 Prospective Randomized Trial Between Needle Fasciotomy and Xiapex for Dupuytrens Contracture Recruiting NCT02476461 Phase 4 xiapex
41 Misoprostol for Reduction of Blood Loss During Fibroid Surgery Recruiting NCT02209545 Phase 4 Misoprostol;Placebo
42 Ulipristal Use in Chinese Population Active, not recruiting NCT02825719 Phase 4 Ulipristal acetate;Ferrous sulphate;Tranexamic Acid
43 Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib Active, not recruiting NCT00756509 Phase 4 Nilotinib
44 Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF Active, not recruiting NCT02647619 Phase 4 Xiapex
45 Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease Enrolling by invitation NCT03406338 Phase 4 Collagenase Clostridium Histolyticum
46 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
47 Preemptive Analgesia Following Uterine Artery Embolization Terminated NCT01555073 Phase 4 pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group
48 Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture Terminated NCT01226121 Phase 4
49 Non-invasive Focal Therapy for Osteoid Osteoma Unknown status NCT02302651 Phase 2, Phase 3
50 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap Unknown status NCT00814073 Phase 3 masitinib (AB1010);placebo

Search NIH Clinical Center for Connective Tissue Cancer

Cochrane evidence based reviews: neoplasms, connective tissue

Genetic Tests for Connective Tissue Cancer

Anatomical Context for Connective Tissue Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Connective Tissue Cancer:

19
Connective Tissue

MalaCards organs/tissues related to Connective Tissue Cancer:

41
Bone, T Cells, Breast, Lung, Bone Marrow, Kidney, Testes

Publications for Connective Tissue Cancer

Articles related to Connective Tissue Cancer:

# Title Authors Year
1
Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET). ( 23446092 )
2013
2
Long-term effects of connective tissue cancer treatment. ( 15346055 )
2004

Variations for Connective Tissue Cancer

Expression for Connective Tissue Cancer

Search GEO for disease gene expression data for Connective Tissue Cancer.

Pathways for Connective Tissue Cancer

GO Terms for Connective Tissue Cancer

Biological processes related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.55 CD34 MDM2 PDGFB TLE1 TP53
2 cellular response to growth factor stimulus GO:0071363 9.43 MDM2 PDGFB TRPV1
3 response to hyperoxia GO:0055093 9.37 CDK4 COL1A1
4 cellular response to alkaloid GO:0071312 9.32 MDM2 TRPV1
5 paracrine signaling GO:0038001 8.96 CD34 PDGFB
6 cellular response to actinomycin D GO:0072717 8.62 MDM2 TP53

Molecular functions related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.23 COL1A1 EWSR1 FUS MDM2 PDGFB TLE1
2 platelet-derived growth factor binding GO:0048407 9.16 COL1A1 PDGFB
3 transcription coregulator activity GO:0003712 9.13 EWSR1 FUS SS18

Sources for Connective Tissue Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....